Skip to main content
Smart Investors Daily
PS

NASDAQ · PSNL

Personalis, Inc.

Healthcare · Medical - Diagnostics & Research

$14.80

Down-$0.91 (-5.79%)

Updated Nov 17, 2026, 2:32 AM

SID Score

5.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
824.5M
P/E ratio
-11.15
Dividend yield
0.00%
52-week range
$4.96 – $18.89
Volume
6.37M
Avg. volume
1.34M

Price performance · PSNL

PSNL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

PSNL closed at $14.80 after 21 trading sessions, down 6.80% for the selected period.

Last close
$14.80
Period change
-6.80%
Period low
$14.80
Period high
$16.00
Daily close
View OHLC price history
PSNL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$15.60$15.69$14.78$14.806.37M
Nov 13, 2026$15.90$15.935$15.575$15.712.8M
Nov 12, 2026$15.90$15.945$15.81$15.861.86M
Nov 11, 2026$15.90$16.04$15.90$15.961.14M
Nov 10, 2026$15.88$16.07$15.805$15.881.76M
Nov 9, 2026$15.80$16.00$15.80$15.952.32M
Nov 6, 2026$15.55$15.81$15.55$15.793M
Nov 5, 2026$15.76$15.85$15.52$15.553.79M
Nov 4, 2026$15.85$15.91$15.69$15.792.22M
Nov 3, 2026$15.90$15.97$15.75$15.752.93M
Nov 2, 2026$15.92$15.93$15.745$15.762.2M
Oct 30, 2026$15.86$15.94$15.645$15.822.36M
Oct 29, 2026$15.98$16.05$15.88$15.925749.24K
Oct 28, 2026$15.93$16.11$15.86$16.001.23M
Oct 27, 2026$15.86$16.13$15.80$15.981.83M
Oct 26, 2026$15.81$15.985$15.77$15.881.14M
Oct 23, 2026$15.73$15.89$15.67$15.851.12M
Oct 22, 2026$15.90$15.96$15.625$15.822.69M
Oct 21, 2026$15.755$16.115$15.755$15.902.79M
Oct 20, 2026$15.94$16.00$15.85$15.942.38M
Oct 19, 2026$15.83$16.0194$15.745$15.883.16M

Latest PSNL news

The latest Smart Investors Daily articles mentioning PSNL.

PSNL research

Overview

Company profile and research snapshot.

Company profile

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$9.50
Implied upside
—
Analysts
13
PSNL recent ratings
DateFirmRatingTarget
Oct 6, 2026BTIGNeutral—
Jul 20, 2026NeedhamHold—
Jul 20, 2026BTIGBuy—
Jul 20, 2026Lake StreetHold—
Jul 17, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 9, 2026

Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report 2026: Capitalize on 13.5% CAGR to $2.4 Billion by 2032 Featuring Covance, Crown Bioscience, Personalis and Promega

Outsourcing to specialized global CROs, supported by AI and NGS, reduces costs, accelerates discovery, lowers failure risk and sharpens focus on commercializationDublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global cancer immunotherapy drug discovery outsourcing market, valued at US$985.6 million in 2025, is projected to reach US$2.4 billion by 2032. The marke

Yahoo · Nov 7, 2026

Did Wider Losses Just Shift Personalis (PSNL) Stock Investment Narrative?

Personalis reported third quarter 2026 sales of US$25.6 million and a net loss of US$33.8 million, with basic loss per share from continuing operations of US$0.32. For the nine month period, the company reported sales of US$63.43 million and a net loss of US$95.52 million, or US$0.90 per share. The earnings update showed higher top line figures alongside wider losses, which highlights ongoing cost intensity and execution pressure as Personalis scales its cancer genomics business. We will...

Yahoo · Nov 4, 2026

Personalis: Q3 Earnings Snapshot

(PSNL) on Wednesday reported a loss of $33.The Fremont, California-based company said it had a loss of 32 cents per share.

Yahoo · Nov 4, 2026

Personalis Reports Third Quarter Results

FREMONT, Calif., November 04, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the third quarter ended September 30, 2026.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.